Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:3.5.1.52 (
PNGase F
)
1,527
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
CMP-sialic acid:lactosylceramide alpha 2,3-sialyltransferase (
SAT-1
) has been purified approximately 40,000-fold to apparent homogeneity from rat liver Golgi. The enzyme was solubilized from Golgi vesicles in 5% lauryldimethylamine oxide and "partially" purified by affinity chromatography twice on CMP-hexanolamine and once on lactosylceramide aldehyde-Sepharose 4B. Final purification was achieved by immunoaffinity chromatography on M12GC7-Gel 10. The M12GC7 monoclonal antibody specifically inhibits and immunoprecipitates
SAT-1
activity. Identification of the protein, with an apparent molecular weight by sodium dodecyl sulfate-polyacrylamide gel electrophoresis of about 60,000 daltons, was confirmed by Western blot and immunodetection with M12GC7.
SAT-1
specifically catalyzes the transfer of N-acetylneuraminic acid (NeuAc, sialic acid) to lactosylceramide (Gal beta 1-4Glc beta 1-O-ceramide), forming GM3 ganglioside. Studies on substrate specificity indicate that the preferred acceptors have the general structure saccharide beta 1-O-ceramide, a disaccharide being preferred to a monosaccharide.
SAT-1
is a glycoprotein. The carbohydrate moieties are detected with specific lectins. Deglycosylation of
SAT-1
with
N-glycanase
results in an increase in a 43,000-dalton band. The two-dimensional electrophoretogram of
SAT-1
indicates a pI range of 5.7-6.2 for the 60,000-dalton protein.
...
PMID:Purification to apparent homogeneity by immunoaffinity chromatography and partial characterization of the GM3 ganglioside-forming enzyme, CMP-sialic acid:lactosylceramide alpha 2,3-sialyltransferase (SAT-1), from rat liver Golgi. 199 28
